n-Lorem Foundation
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2020-01-01
- Employees
- 1
- Market Cap
- -
- Website
- https://www.nlorem.org
Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- n-Lorem Foundation
- Target Recruit Count
- 1
- Registration Number
- NCT06977451
- Locations
- 🇺🇸
Columbia University, Irving Medical Center, New York, New York, United States
Personalized Antisense Oligonucleotide Therapy for A Single Participant With LMNB1 Mutation Associated Autosomal Dominant Leukodystrophy (ADLD)
Phase 1
Active, not recruiting
- Conditions
- Autosomal Dominant Leukodystrophy
- Interventions
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- n-Lorem Foundation
- Target Recruit Count
- 1
- Registration Number
- NCT06816498
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Personalized Antisense Oligonucleotide Therapy for a Single Participant with ATN1 Gene Mutation
Phase 1
Active, not recruiting
- Conditions
- Dentatorubral-Pallidoluysian Atrophy
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- n-Lorem Foundation
- Target Recruit Count
- 1
- Registration Number
- NCT06706388
- Locations
- 🇺🇸
Columbia University, New York, New York, United States
Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- n-Lorem Foundation
- Target Recruit Count
- 1
- Registration Number
- NCT06392126
- Locations
- 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath